Prism AI Therapeutics is delighted to join the BLOODPAC community and to work with the other members on advancing precision medicine for patients around the world. BLOODPAC has been blazing the trail for better industry collaboration, data sharing, policy creation and protocol standardization that can accelerate the development of life saving diagnostic and therapeutic products.
AI-driven disease models provide an exciting opportunity for disease screening and drug development; however, limited access to high-quality and clinically annotated human molecular data for model training significantly limit the applicability of most supervised AI/ML tools.
Prism AI Therapeutics provides an end-to-end solution to this problem. This solution includes global clinically annotated biospecimen sourcing, molecular lab processing, and AI/ML multi-omics data integration, harmonization, batch-effect cancellation between sites, and platforms and generation of interpretable disease/drug models in a federated learning fashion. Our patented technology, based on quantum mechanics, can detect novel molecular and mechanistic signals in multi-dimensional data with millions of features and a small number of patients.
We are bringing together an ALL-STAR team to build our platform and to support our customers. We are glad to have this opportunity to welcome some of our newest family members:
Daniel Shabtai – Our Co-Founder and CTO, brings over a decade of experience from Meta, where he spearheaded critical engineering organizations. He built Facebook's video experience from the ground up, laying the foundation for today's global video consumption and driving billions of dollars in quarterly revenue for Meta. Additionally, he led technology efforts to scale the company by 10X through innovative HR engineering products. Furthermore, he led Meta's Integrity Automation organization, identifying and addressing harmful content and actors across all of Meta's platforms (Instagram, WhatsApp, Facebook, Messenger, Oculus). His expertise in AI/ML, scalable systems, and data privacy has powered products used by billions worldwide. Prism AI is bringing Daniel back to his passion for research work in the bioinformatics drug research field, which he pursued during his graduate studies.
Jason Friske, CPA - Our Fractional VP Finance, brings 20 years of experience in the Accounting & Finance field, with the last 10 years focused on startup businesses in the life science and technology space. Most recently, Jason helped deliver the sale of C2i Genomics, Inc. to Veracyte in less than 30 days from announcement to closing, highlighting his mastery of administration. Before that, Jason oversaw the rapid growth of Opentrons and the Pandemic Response Labs in NYC from $50M to $200M in just 1 year during the unprecedented COVID pandemic. During that time, he helped to close a $40M credit facility with JPM and a $175M Series C with Softbank as the lead investor.
We’re excited to welcome Prism AI Therapeutics to the BLOODPAC community! Prism AI specializes in precision therapeutics, helping biotech companies and health systems to unlock molecular insights from their data and develop life-saving drugs and diagnostics with their AI-first clinical multi-omic data management platform.
Using patented quantum mechanics-based technology, Prism AI is overcoming challenges in biomarker discovery leveraging real-world clinico-molecular data.
Welcome to the BLOODPAC!
